Virax Biolabs Group Limited

VRAX

KYG9495L1335

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 25/07/2026 am IST			5-day change	1st Jan Change
3.190 ^USD	0.00%		-15.83%	-63.10%

10/07	Top Midday Decliners	MT
10/07	Top Premarket Decliners	MT

Top Premarket Decliners

Published on 07/10/2026 at 05:06 pm IST

MT Newswires

Add MarketScreener to your sources

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Virax Biolabs Group Limited

10/07	Top Midday Decliners	MT
10/07	Top Premarket Decliners	MT
06/07	Virax Biolabs Group Limited Reports Earnings Results for the Full Year Ended March 31, 2026	CI
06/07	Virax Biolabs Group Limited Auditor Raises 'Going Concern' Doubt	CI
24/06	Virax Biolabs to Implement 1-for-25 Share Consolidation	MT
26/05	Virax Biolabs Group Limited Reports Positive Early Clinical Data for Viraximmune in Long Covid and Related Post-Acute Infection Syndromes	CI
19/03	Virax Biolabs Group Limited Approves Fourth Amended and Restated Memorandum and Articles of Association	CI
04/12	Virax Biolabs Group Limited announced that it has received $4.99875 million in funding	CI
03/12	Virax Biolabs Group Limited announced that it expects to receive $4.99875 million in funding	CI
03/12	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2025	CI
03/11	Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive Fda Feedback for Viraximmune?? Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes	CI
26/25/26	Virax Biolabs to Collaborate With Emory University on Long COVID Clinical Studies	MT
26/25/26	Virax Biolabs partners with Emory University on ViraxImmune(TM) clinical studies	RE
26/25/26	Virax Biolabs Group Limited Partners with Emory University on ViraxImmune Clinical Studies	CI
30/25/30	Virax Biolabs Group Limited Announces Board Changes	CI

Chart Virax Biolabs Group Limited

Duration

Period

VRAX: Dynamic Chart

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individualâ€™s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).

Employees

Sector

Biotechnology & Medical Research

More about the company